A 4-week versus a 3-week schedule of gemcitabine monotherapy for advanced pancreatic cancer: A randomized phase II study to evaluate toxicity and dose intensity

International Journal of Clinical Oncology

Volumn 16, Issue 6, 2011, Pages 637-645

  Hirao, Ken ^a   Kawamoto, Hirofumi ^a   Sakakihara, Ichiro ^a   Noma, Yasuhiro ^a   Yamamoto, Naoki ^a   Harada, Ryo ^a   Tsutsumi, Koichiro ^a   Fujii, Masakuni ^a   Kato, Hironari ^a   Kurihara, Naoko ^a   Mizuno, Osamu ^a   Ogawa, Tsuneyoshi ^a   Ishida, Etsuji ^a   Yamamoto, Kazuhide ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

3 week schedule; 4 week schedule; Chemotherapy; Dose intensity; Gemcitabine; Pancreatic cancer

Indexed keywords

GEMCITABINE;

ADULT; ADVANCED CANCER; ADVERSE OUTCOME; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHOLANGITIS; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; CYSTITIS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME BLOOD LEVEL; FATIGUE; FEMALE; FEVER; HUMAN; INTERSTITIAL PNEUMONIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PYELONEPHRITIS; RADIATION PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; URTICARIA;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA; PANCREATIC NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84855186532     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-011-0237-z     Document Type: Article

References (18)

1. DM Parkin F Bray J Ferlay, et al. 2005 Global cancer statistics 2002 CA Cancer J Clin 55 2 74 108 15761078 10.3322/canjclin.55.2.74
2. A Jemal R Siegel E Ward, et al. 2008 Cancer statistics 2008 CA Cancer J Clin 58 2 71 96 18287387 10.3322/CA.2007.0010 (Pubitemid 351521864)
3. E Mitry B Rachet MJ Quinn, et al. 2008 Survival from cancer of the pancreas in England and Wales up to 2001 Br J Cancer 99 Suppl 1 S21 S23 18813249 10.1038/sj.bjc.6604576
4. N Starling D Cunningham 2008 Survival from cancer of the pancreas in England and Wales up to 2001 Br J Cancer 99 Suppl 1 S24 S25 18813250 10.1038/sj.bjc.6604577
5. JL Abbruzzese 1996 Phase I studies with the novel nucleoside analog gemcitabine Semin Oncol 23 5 Suppl 10 25 31 8893878 1:CAS:528:DyaK28XmvFWrtbY%3D (Pubitemid 26362191)
6. HA Burris 3rd MJ Moore J Andersen, et al. 1997 Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 6 2403 2413 9196156 1:CAS:528:DyaK2sXlsFKksLY%3D (Pubitemid 27251144)
7. M Reni S Cordio C Milandri, et al. 2005 Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial Lancet Oncol 6 6 369 376 15925814 10.1016/S1470-2045(05)70175-3 1:CAS:528:DC%2BD2MXltFWktLw%3D (Pubitemid 40753742)
8. MJ Moore D Goldstein J Hamm, et al. 2007 Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 25 15 1960 1966 17452677 10.1200/JCO.2006.07.9525 1:CAS:528:DC%2BD2sXmvVWmsr0%3D (Pubitemid 46972777)
9. R Herrmann G Bodoky T Ruhstaller, et al. 2007 Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group J Clin Oncol 25 16 2212 2217 17538165 10.1200/JCO.2006.09.0886 1:CAS:528:DC%2BD2sXnsVShtbw%3D (Pubitemid 46954645)
10. D Cunningham I Chau DD Stocken, et al. 2009 Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer J Clin Oncol 27 33 5513 5518 19858379 10.1200/JCO.2009.24.2446 1:CAS:528:DC%2BC3cXhtVWitrc%3D
11. S Okada H Ueno T Okusaka, et al. 2001 Phase I trial of gemcitabine in patients with advanced pancreatic cancer Jpn J Clin Oncol 31 1 7 12 11256843 10.1093/jjco/hye003 1:STN:280:DC%2BD3M7mtFSitg%3D%3D (Pubitemid 32236880)
12. M Fukuoka S Negoro S Kudo, et al. 1996 Late phase II study of LY188011 (gemcitabine hydrochloride) in patient with non-small-cell lung cancer. Gemcitabine Late Phase II Cooperative Study Group A Gan To Kagaku Ryoho 23 13 1825 1832 8937493 1:STN:280:DyaK2s%2FptFyhtQ%3D%3D (Pubitemid 26398837)
13. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 3 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D
14. W Hryniuk E Frei 3rd FA Wright, et al. 1998 A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: summation dose-intensity J Clin Oncol 16 9 3137 3147 9738586 1:CAS:528:DyaK1cXmtFSlsb8%3D (Pubitemid 28417437)
15. R Simon RE Wittes SS Ellenberg, et al. 1985 Randomized phase II clinical trials Cancer Treat Rep 69 12 1375 1381 4075313 1:STN:280:DyaL28%2FnvFahtQ%3D%3D (Pubitemid 16163075)
16. H Soto Parra R Cavina F Latteri, et al. 2002 Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study Ann Oncol 13 (7 1080 1086 12176787 10.1093/annonc/mdf186 1:STN:280: DC%2BD38vitFWnsQ%3D%3D
17. M Hidalgo D Castellano L Paz-Ares, et al. 1999 Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer J Clin Oncol 17 2 585 592 10080603 1:CAS:528: DyaK1MXht1Wmu70%3D (Pubitemid 29075246)
18. HS Shiah AL Cheng C Hsu, et al. 2006 Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer J Gastroenterol Hepatol 21 3 531 536 16638094 10.1111/j.1440-1746.2005. 03957.x 1:CAS:528:DC%2BD28XltFaiu7g%3D